26. DIARRHEA

Published on 09/04/2015 by admin

Filed under Hematology, Oncology and Palliative Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1371 times

CHAPTER 26. DIARRHEA
Debra E. Heidrich

DEFINITION AND INCIDENCE

Diarrhea is defined as an increase in stool volume and liquidity, resulting in the passage of three or more loose or unformed stools per day (Carpenito, 2000; Rogers, 2005; Sykes, 2003). This symptom, however, is somewhat subjective: some may report three soft stools in a day as diarrhea, but others may report only stools that are liquid and occur in large volume. Diarrhea is often associated with abdominal cramping and rectal urgency (Carpenito, 2000; Levy, 1991). Uncontrolled diarrhea can lead to fluid and electrolyte imbalances, resulting in lethargy, weakness, and orthostatic hypotension. In addition, persistent diarrhea may lead to malnutrition, impaired skin integrity, altered sleeping patterns, social isolation, anxiety, and self-concept disturbances.
Approximately 7% to 10% of persons with advanced cancer report diarrhea (Sykes, 2003; Waller & Caroline, 2000), and 50% or more of those with human immunodeficiency virus (HIV) disease may experience this symptom (Cohen, West, & Bini, 2001; Sykes, 2003). The number of acquired immunodeficiency virus (AIDS) patients admitted to the hospital for uncontrolled diarrhea has decreased with the use of highly active antiretroviral therapy. A review of data from the state of New York in 1998 revealed that of the 15,000 persons with AIDS admitted to hospitals, 2.8% had a diarrheal diagnosis (Anastasi & Capili, 2000). This study did not indicate the number of persons with AIDS who experience diarrhea that is not severe enough to warrant hospitalization. Even mild to moderate diarrhea can have debilitating effects. Sanchez, Brooks, Sullivan et al. (2005) reported that although the incidence of bacterial diarrhea in patients with HIV disease decreased over the decade of 1992 to 2002, there is still an increased incidence over the general population and the risk of diarrhea increases with increased severity of HIV disease.
Most diarrhea is acute, lasting only a few days, and is generally due to infection or overuse of laxatives. Diarrhea that lasts longer than 3 weeks is considered chronic and is usually due to organic disease (Sykes, 2003).

ETIOLOGY AND PATHOPHYSIOLOGY

The three most common causes of diarrhea in persons with advanced cancer are laxative overdose, fecal impaction with overflow diarrhea, and partial bowel obstruction (Sykes, 2003; Mercadante, 2002). Other common causes are radiation enteritis, medications, and steatorrhea. In persons with AIDS, infection is often the cause, although the pathogen is not always identifiable.
Any condition that increases secretion within the gastrointestinal (GI) tract, interferes with reabsorption from the GI tract, increases the motility of the GI tract, or causes excretion of mucus, fluids, or blood can cause diarrhea. These correspond with the general mechanisms of diarrhea: secretory, osmotic, hypermotile, and exudative (Lingappa, 2003). Diarrhea in the terminally ill often involves more than one mechanism. The pathophysiological characteristics of these mechanisms are discussed later. Table 26-1 includes many of the conditions that lead to diarrhea in the palliative care setting, the pathophysiological mechanism(s), descriptors that may be helpful in determining the type and cause of this symptom, and suggested interventions.
TABLE 26-1 Causes, Character, and Treatment of Diarrhea
Data from Benson, C.A., Kaplan, J.E., Masur, H., et al. (2004). Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases of Society of America. Retrieved November 15, 2005, from www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm; Bickley, L.S. (2004). The abdomen. In L.S. Bickley, Bates’guide to physical examination and history taking (8th ed., pp.355-386). Philadelphia: Lippincott; Mercadante, W. (2002). Diarrhea, malabsorption, and constipation. In A. Berger, R. Portenoy, & D. Weissman (Eds.). Principles and practice of palliative and supportive oncology (2nd ed., pp.233-249). Philadelphia: Lippincott Williams & Wilkins; Levy, M.H. (1991). Constipation and diarrhea in cancer patients. Cancer Bull, 43, 412-422; Rogers, H.M. (2005). Management of clients with intestinal disorders. In J.M. Black & J.H. Hawks (Eds.). Medical-surgical nursing: Clinical management for positive outcomes (7th ed., pp.807-855). St. Louis: Elsevier Saunders; Sykes, N. (2003). Constipation and diarrhoea. In D. Doyle, G. Hanks, N.I. Cherny, et al. (Eds.). Oxford textbook of palliative medicine (3rd ed., pp.483-496). New York: Oxford University Press; and Woodruff, R. & Glare, P. (2003). AIDS in adults. In D. Doyle, G. Hanks, N.I. Cherny, et al. (Eds.). Oxford textbook of palliative medicine (3rd ed., pp.847-880). New York: Oxford University Press.
Cause Mechanism(s) Descriptors Treatment
Cancer-Related Diarrhea
Endocrine-producing tumor Secretory via production or stimulation of secretagogues
High volume, watery
Associated with abdominal cramping
Encourage or replace fluids, as needed
Control diarrhea: antidiarrheals
Inhibit intestinal secretion (if severe): octreotide, clonidine
Treat pain: anticholinergics
Obstruction Exudative and hypermotility Alternating constipation and diarrhea, often with mucus and blood; colicky pain
Reduce inflammation: steroids
Treat pain: anticholinergics
Control diarrhea: cautious use of antidiarrheals
Biliary or pancreatic obstruction Osmotic due to fat malabsorption Steatorrhea: large volume, pale, foul odor; feces floats in toilet
Decrease dietary fat
Treat fat malabsorption: pancreatic enzymes, famotidine
Cancer Treatment–Related Diarrhea
Chemotherapy Secretory due to damage to villi, inhibiting absorption; hypermotility due to irritation
High volume, watery; may be explosive
Associated with colicky pain
Encourage or replace fluids, as needed
Slow motility: antidiarrheals
Inhibit intestinal secretion (if severe): octreotide, clonidine
Treat pain: anticholinergics
Radiation therapy
▪ Acute
Secretory (due to inflammation and bile salt malabsorption), osmotic, and hypermotility due to effects of bile salts
High volume, watery, explosive
Associated with abdominal cramping
Usually self-limiting
Encourage or replace fluids, as needed
Treat inflammation: nonsteroidal anti-inflammatory drugs
Absorb bile salts: cholestyramine
Slow motility: antidiarrheals
Radiation therapy
▪ Chronic (may occur 5 to 15 years after treatment)
Ischemic enteritis, ulcerations, or impaired cellular functioning; may be secretory and/or osmotic Depends on mechanism; generally high volume and watery
Encourage or replace fluids, as needed
Control diarrhea: antidiarrheals
Absorb bile salts: cholestyramine
Surgery
▪ Gastrectomy
Secretory, osmotic, and hypermotility due to “dumping syndrome” and potential for bile salt malabsorption
High volume with undigested food
Associated with nausea, vomiting, flatulence, and colicky pain
Frequent, small meals
Control diarrhea: antidiarrheals
Bile salt malabsorption: cholestyramine
Treat pain: simethicone for gas pain; anticholinergics for colicky pain
Surgery
▪ Ileal resection
Secretory, osmotic, and hypermotility due to poor reabsorption of bile salts High volume with undigested food
Frequent, small meals
Control diarrhea: antidiarrheals
Bile salt malabsorption: Cholestyramine
Treat pain: simethicone for gas pain; anticholinergics for colicky pain
Surgery
▪ Short bowel syndrome
Osmotic due to decreased fluid absorption Depends on length of bowel resected: loose to watery
Increase bulk of stool: bulk-forming laxatives
Slow motility: antidiarrheals
Infection-Related Diarrhea
Noninflammatory infections (e.g., viruses, Escherichia coli, Staphylococcus aureus) Secretory due to stimulation of secretagogues via endotoxins
Often self-limiting
Watery, without pus or mucus
Associated with periumbilical cramping, nausea, and vomiting
Temperature normal or slightly elevated
If prolonged:
Treat infection, when possible
Encourage or replace fluids, as necessary
Control diarrhea: antidiarrheals, using bismuth subsalicylate (Pepto-Bismol) as first choice, if required
Treat pain: anticholinergics
Inflammatory infections (e.g., Shigella, Salmonella, Campylobacter spp., invasive E. coli) Secretory
Loose to watery, often with blood, pus, or mucus
Associated with lower abdominal cramping, rectal urgency, and fever
Treat infection, when possible
Encourage or replace fluids, as necessary
Control diarrhea: antidiarrheals
Treat pain: anticholinergics
Cryptosporidiosis Secretory High volume, watery, explosive; associated with abdominal cramping, fever, and vomiting
Treat immunosuppression: antiretroviral therapy
Treat infection: nitazoxamide or paramomycin
Encourage or replace fluids, as necessary
Control diarrhea: antidiarrheals
Treat pain: anticholinergics
Other Treatment-Related Diarrhea
Overuse of laxatives Depends on type(s) of laxative; usually osmotic or hypermotility Frequent, loose stools Discontinue or decrease dose of laxatives
Impaction Exudative
Rectal leakage with too much softener; cramping with too much stimulant
Small amounts of dark, mucuslike liquid; rectal pressure
Perform disimpaction
Begin or adjust laxative protocol
Enteral supplements or feedings Osmotic due to hyperosmolality of supplement or due to lactose intolerance
Large volume and watery
Associated with abdominal cramping, distension, and flatulence
Low stool pH
Dilute supplement with water and gradually increase strength
Consider using bulk-forming agents
Evaluate need for lactose-free supplement
Celiac plexus block Hypermotility due to suppression of sympathetic nervous system
Moderate to large volume, loose stool
May be self-limiting
Slow motility: antidiarrheals; anticholinergics
Anxiety Hypermotility and secretory of lower gastrointestinal tract via parasympathetic stimulation
Generally moderate to large volume; loose stool
Stool may contain mucus
Treat anxiety: address psychosocial concerns;
Teach relaxation techniques;
Evaluate need for anxiolytic
Medication Often secretory Secretory is generally large volume; but diarrhea character may vary with offending medication Stop offending medication, when possible

Pathophysiological Characteristics of Secretory Diarrhea

The lining of the walls of the small intestine includes small pits, called the crypts of Lieberkühn, that lie between the intestinal villi. The crypts produce the four cell types of villi: enterocytes, goblet cells, enteroendocrine cells, and Paneth cells. The mucus of the goblet cells lubricates and protects the surfaces of the bowel lumen. The enterocytes of the crypts secrete large quantities of water and electrolytes, and those of the villi reabsorb water and electrolytes along with the products of metabolism. The enteroendocrine cells secrete hormones into the bloodstream, and the Paneth cells produce antimicrobial peptides and growth factors (Lingappa, 2003). Active secretion that overwhelms the absorptive processes of the GI tract leads to diarrhea that generally persists with fasting (Mercadante, 2002). Substances that increase bowel secretions (secretagogues) include vasoactive intestinal polypeptide, calcitonin, serotonin, bradykinin, substance P, prostaglandins, and gastrin (Levy, 1991; Lingappa, 2003; Mercadante, 2002). Conditions that lead to the production of one or more of these secretagogues include the following:
▪ Inflammation in the bowel wall causes the release through the cyclooxygenase pathway of prostaglandins, which stimulate bowel secretions. In addition, the inflammation interferes with the absorption process, further contributing to diarrhea (Mercadante, 2002). This is the likely mechanism for the diarrhea associated with acute radiation enteritis, chemotherapy, and infection.
▪ Two infections that lead to significant fluid and electrolyte losses from secretory diarrhea are cryptosporidiosis and pseudomembranous colitis. Cryptosporidium sp., a common cause of diarrhea in the AIDS population, attaches to the intestinal epithelium. It damages the enterocytes, leading to impaired absorption and enhanced secretion within the intestinal tract (Rogers, 2005). The diarrhea of cryptosporidiosis is profuse and watery and is associated with abdominal cramping, fever, and vomiting (Woodruff & Glare, 2003). Pseudomembranous colitis is caused by colonization with Clostridium difficile after antibiotic therapy. C. difficile produces toxins that damage the mucosa, leading to a secretory diarrhea (Rogers, 2005). Symptoms begin within 1 week to 1 month of starting antibiotic therapy.
▪ Certain tumors, including small-cell lung cancer, ganglioneuroma, pheochromocytoma, carcinoma of thyroid, malignant carcinoids, and gastrinomas, produce one or more of these secretagogue substances (Mercadante, 2002).
▪ The inability to reabsorb bile acids from the small intestine leads to diarrhea via the secretory effect of these substances on the mucosa of the colon and their osmotic effect in the colon. The result is diarrhea that is watery and explosive (Mercadante, 2002; Sykes, 2003). Ileal resection, gastrectomy with vagotomy, and postirradiation enteritis may interfere with bile acid reabsorption.
▪ Some medications, such as caffeine, theophylline, antacids, some antibiotics, and poorly absorbable osmotic laxatives, also cause secretory diarrheas via direct simulation of secretions or secondary to irritation of the epithelial cells (Mercadante, 2002).

Pathophysiological Characteristics of Osmotic Diarrhea

Persons with lactose intolerance and those receiving high-carbohydrate supplements or enteral feedings are at risk for osmotic diarrhea. The sorbitol in sugar-free elixirs and enteral feedings is often overlooked as a cause of this symptom (Sykes, 2003). The overuse of osmotic laxatives is also a cause of diarrhea for some persons with advanced disease.
Malabsorption of fat is another cause of osmotic diarrhea. Most dietary intake of fat is absorbed in the small intestines and only small amounts of lipids enter the colon. The absorption of fat from the small intestines is dependent on pancreatic enzymes to break down the fats and bile salts to make the fat particles soluble. Pancreatic cancer or resection of the pancreas may cause a deficiency of pancreatic enzymes, leading to malabsorption of fat and steatorrhea. Biliary tract obstruction, terminal ileal resection, and cholestatic liver disease cause a decrease in bile salt formation, again contributing to malabsorption of fat and steatorrhea (Mercadante, 2002). Steatorrhea is characterized by loose, pale, foul-smelling feces. The feces may be greasy in appearance and tend to float in the toilet, making them difficult to flush.

Pathophysiological Characteristics of Diarrhea Due to Hypermotility

When GI tract motility is abnormally stimulated, bowel contents are moved through the intestines too quickly to prevent adequate absorption, leading to diarrhea. Several factors may contribute to GI hypermotility.
Parasympathetic stimulation enhances GI motility and leads to diarrhea. Both the small and the large intestines receive parasympathetic stimulation from the vagus and the hypogastric plexus. Stimulation of the sympathetic nervous system inhibits activity of the GI tract and generally acts to balance parasympathetic activity. Sympathetic innervation originates in the celiac, superior mesenteric, inferior mesenteric, and hypogastric ganglia (Rogers, 2005). If sympathetic activity is blocked, leaving the parasympathetic activity unopposed, hypermotility and diarrhea may result. This is the likely mechanism for the diarrhea associated with celiac plexus block (Mercadante, 2002).
▪ Irritation of the small or large bowel may stimulate an increase in peristaltic activity. In addition to causing increasing secretions in the GI tract, food poisoning and infections may directly irritate the small bowel and increase motility. This is generally considered a protective mechanism to rid the body of the irritative substance. Ulcerative colitis and tumors of the large bowel may similarly increase the motility of the large bowel due to direct irritation.
▪ Medications that increase bowel motility, including stimulant laxatives and cholinergics (e.g., metoclopramide), may also lead to diarrhea.

Pathophysiological Characteristics of Exudative Diarrhea

The presence of serum proteins, blood, or excessive amounts of mucus in the bowel contributes to diarrhea.
▪ Tumors of the bowel or any GI ulceration may cause bleeding into an intestinal lumen. Blood, like serum proteins, has an osmotic effect.
▪ The large intestine has many crypts of Lieberkühn lined with epithelial cells. The primary purpose of these epithelial cells is to secrete mucus. Normally, this mucus serves to lubricate the bowel lumen and soften the stool. In the presence of abnormal stimulation, as may occur with tumors, partial or complete bowel obstruction, or impactions, excessive amounts of mucus may be secreted.

Diarrhea in AIDS Patients

Most diarrheas in AIDS patients are due to infection. Although some pathogens are those that also infect immunocompetent patients, most are opportunistic infections. Cytomegalovirus and cryptosporidiosis are the most common forms of diarrhea in HIV-infected patients, but other protozoan, viral, fungal, and bacterial infections are also seen in this population (Cohen et al., 2001).

ASSESSMENT AND MEASUREMENT

A thorough assessment and physical examination of the patient are required to identify the causes of diarrhea and guide appropriate intervention. Measurement of the severity of diarrhea is based on the number and quantity of loose stools per day and any associated symptoms. The National Cancer Institute developed a grading tool for diarrhea severity related to cancer treatment on a 0-to-4 scale (Table 26-2). This scale is useful in categorizing responses to treatment for research purposes and could be used in the clinical setting. However, many patients and health care practitioners use the number of diarrhea stools per day as a “rating scale.” The rating scale used must be clear to all persons since a 4 on the NCI scale is very different from having four diarrhea stools in 1 day.
TABLE 26-2 Common Toxicity Criteria for Diarrhea
Modified from National Cancer Institute. (2003). Common terminology criteria for adverse events version 3.0. Bethesda, Md.: Author. Retrieved November 14, 2005, from http://ctep.cancer.gov/forms/CTCAEv3.pdf. © 2005
GRADE
0 1 2 3 4
Symptoms None Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline Increase of 4 to 6 stools per day over baseline; IV fluids indicated for less than 24 hr; moderate increase in ostomy output compared to baseline; not interfering with activities of daily living Increase to 7 or more stools per day over baseline; incontinence; IV fluids for 24 hr or longer; hospitalization; severe increase in ostomy output compared to baseline; interfering with activities of daily living Life-threatening consequences (e.g., hemodynamic collapse)
The character and amount of diarrhea provide clues regarding the underlying cause.
▪ Disorders of the small intestine or proximal colon tend to cause large amounts of diarrhea that is light in color and watery or greasy. Undigested food may be present, but blood usually is not.
▪ Disorders of the left side of the colon or rectum tend to cause small amounts of diarrhea that is dark in color and contains mucus or blood. This diarrhea may also be accompanied by a sense of rectal urgency (Mercadante, 2002).
▪ Stools that are pale and fatty and have an offensive odor indicate steatorrhea and fat malabsorption.
▪ Diarrhea that follows several days of constipation suggests fecal impaction or partial obstruction (Mercadante, 2002; Sykes, 2003).
▪ Osmotic diarrheas tend to stop with fasting, whereas diarrhea that persists after a 2- or 3-day fast suggests a secretory process. Hypermotility disorders are suspected when osmotic and secretory diarrhea is ruled out (Levy, 1991).
▪ General history
Terminal diagnosis and its potential effect on bowel functioning or risk of infection
Bowel tumors
Immunosuppression
History of chronic bowel diseases (e.g., ulcerative colitis)
History of food intolerances or allergies, especially intolerance of milk or milk products due to lactase deficiency
Recent history of chemotherapy
Recent or past history of radiation therapy
Recent food and fluid intake, including alcohol consumption
Current medications:
Laxatives (excessive stimulative laxatives cause colic and urgency; excessive softening leads to fecal leakage) (Sykes, 2003)
Antibiotics
Any new medication
▪ Diarrhea history
Duration (how long diarrhea has been present)
Whether diarrhea was preceded by constipation
Frequency (number of diarrhea stools in 24 hours)
Timing (times of day when diarrhea is worse or absent):
Association with intake of food or fluids
Wakening of the patient from sleep
Quantity (size of diarrhea stools):
Consistency (e.g., semiformed, unformed, liquid)
Color (light or dark)
Other characteristics (e.g., foul odor, tendency to float in toilet)
▪ Physical examination
Auscultate bowel sounds:
Hyperactivity with most diarrheas
Intestinal obstruction indicated by high-pitched sounds accompanied by abdominal cramping (Bickley, 2004)
Palpate abdomen for fecal or tumor mass
Note any ascites or abdominal distension
Examine the rectum for tone, presence of feces in ampulla, or signs of rectal discharge
Assess the presence of fever, indicative of an infectious process
Note any signs of dehydration:
Postural hypotension
Poor skin turgor
Decreased urine output
Assess nutritional status (in advanced diseases, it may be difficult to determine whether the cause of poor nutritional status is related more to terminal illness or to malabsorption of nutrients)

DIAGNOSTICS

Often, a careful history and clinical examination identify the cause of diarrhea and further diagnostic evaluation is not necessary. If information is not sufficient, examination of the stool for pus, blood, fat, and ova and parasites, as well as stool culture, may be appropriate (Mercadante, 2002; Sykes, 2003). Guaiac-positive diarrhea indicates an exudative mechanism, such as chronic radiation colitis, cancerous tumor, or infectious diarrhea.
Bowel obstructions are often diagnosed on the basis of findings from the patient’s history and physical examination. Abdominal radiography to confirm a bowel obstruction is generally not necessary in palliative care settings. If a surgical intervention for the bowel obstruction is a consideration, radiography is appropriate.
Calculating the stool osmolality anion gap (stool osmolality anion gap = stool osmolality − 2 [stool sodium + stool potassium]) can assist in determining whether the diarrhea is osmotic or secretory:
▪ If the stool osmolality anion gap is more than 50 mmol/L, the diarrhea is osmotic.
▪ If the stool osmolality anion gap is less than 50 mmol/L, the diarrhea is secretory.
In addition to calculation of the anion gap, the presence of secretory agents in the serum, such as vasoactive protein, gastrin, and calcitonin, may indicate a secretory diarrhea (Levy, 1991).
Endoscopy, biopsy, or barium radiography may be necessary to determine the cause of inflammatory processes (Levy, 1991). The patient’s physical status and ability to tolerate the procedure, as well as the likelihood of identifying a treatable cause of the diarrhea, are important considerations when determining the appropriateness of these invasive, uncomfortable procedures.

INTERVENTION AND TREATMENT

Appropriate interventions are aimed at treating reversible causes of diarrhea, preventing complications, promoting comfort, and improving quality of living.

General Measures

Discontinue any laxatives and begin a clear liquid diet to promote bowel rest. It is helpful to avoid very hot and very cold foods, as well as any milk products. Gradually, add semisolids such as bananas, rice, applesauce, and crackers or plain toast. The diet can be advanced as tolerated. Encourage a gluten-free diet to reduce abdominal cramping, and avoid fatty foods, whole grain products, and fresh fruits and vegetables.
Monitor hydration status by tracking intake and output. Most diarrhea in palliative care other than HIV-associated diarrhea is rarely of sufficient amount or duration to require rehydration (Sykes, 2003). When rehydration is necessary, oral hydration is preferred. The rehydration solution should contain glucose, electrolytes, and water. Use commercial sports drinks (e.g., Gatorade) or dextrose and electrolyte solutions available at pharmacies (e.g., Resol, Rehydralyte, Pedialyte). As an alternative, make a solution of ½ teaspoon salt, ½ teaspoon baking soda, and 4 tablespoons sugar in 1 liter of water (Carpenito, 2000). The World Health Organization’s recommended rehydration solution is 2 g of salt plus 2 g of sugar in 1 liter of water. This can be flavored with lemon juice if desired (Waller & Caroline, 2000). Homemade solutions should be used within 24 hours of preparation. Intravenous or hypodermoclysis replacement may be required if the patient is unable to tolerate sufficient oral intake.
It is essential to provide good skin care. Keep the perianal area clean and protected. Avoid rubbing the area with wash clothes or towels. Use a pH-balanced cleanser or warm water applied using a squeeze bottle with gentle pressure. Sitz baths also help cleanse and promote comfort. Avoid soaps, since they are drying. After cleansing, apply a moisturizer followed by a barrier that contains zinc oxide, dimethicone, or silicone. Petrolatum-based products should be avoided, since they need to be reapplied frequently (Fleck, 2005). If the patient is experiencing massive amounts of diarrhea, consider the use of a fecal incontinence bag to protect skin, decrease caregiver burden, and help control odor.

Treat Cause of Diarrhea

▪ If the diarrhea is related to medications, stop the offending agents(s) when possible.
▪ If the diarrhea is due to fecal impaction, perform a manual disimpaction. Premedicate patients for this procedure. Waller and Caroline (2000) suggest sedation with midazolam, 1 mg intravenously, titrated up by 0.5-mg increments as needed, plus morphine. An oral benzodiazepine and opioid are also effective if the patient is premedicated 1 to ½ hours before the procedure. Provide local anesthesia by applying lidocaine jelly onto the anus and then instilling 10 ml of 1% lidocaine jelly into the rectum. Wait 10 minutes before performing the digital removal of stool (Waller & Caroline, 2000). Following disimpaction, adjust laxatives to prevent future constipation.
▪ If the diarrhea is caused by infection, assess the potential of treating the infection. In acute, self-limited diarrhea, such as common viral-related diarrhea, no antiinfective treatment may be necessary. When pseudomembranous colitis is suspected, begin metronidazole, 500 mg orally every 8 hours for 10 days. Vancomycin, 125 to 250 mg orally every 6 hours for 10 days, should be reserved for second-line therapy (Hodgson & Kizior, 2004; Poutanen, 2004; Sykes, 2003).
▪ For more prolonged infection-related diarrhea, which most often occurs in the AIDS population, the antiinfective is ideally selected based on the documented causative agent. Evaluation of the patient’s physical status and preferences regarding treatment and the likelihood of disease response to treatment is essential in planning appropriate treatment. Doses of antiinfective treatments often need to be reduced in the presence of renal dysfunction. Consultation with an infectious disease specialist is recommended:
AIDS patients with diarrhea respond better to antidiarrheal therapy and have fewer relapses of diarrhea when concurrently treated with antiretroviral therapy or protease inhibitors (Cohen et al., 2001; Maggi, Larocca, Quarto et al., 2000). Currently, there is debate on whether to continue an antiinfective at a maintenance dose after treatment of the acute infection in persons who are receiving highly active antiretroviral therapy (Aberg, Williams, Liu et al., 2003; Benson, Kaplan, Masur et al., 2004; Cohen et al., 2001).
Cryptosporidiosis is best treated by effective antiretroviral therapy. Alternatively, nitazoxanide 500 mg orally every 12 hours for 3 days or paramomycin 25 to 35 mg/kg orally in three divided doses for 5 to 6 days (Benson et al., 2004) can be used.
Salmonella spp. are usually treated with ciprofloxacin 500 to 750 mg orally twice daily. Duration of therapy for mild gastroenteritis is 7 to 14 days, and for advanced HIV therapy, it is continued for 4 to 6 weeks. Ciprofloxacin 500 mg orally twice daily may be continued for chronic suppression therapy (Benson et al., 2004).
Isospora belli sp. are effectively treated with trimethoprim-sulfamethoxazole 80 to 160 mg/400 to 800 mg orally twice daily to four times daily for 10 days (Cohen et al., 2001; Verdier, Fitzgerald, Johnson et al, 2000; Woodruff & Glare, 2003).
Cytomegalovirus often responds to treatment with ganciclovir or foscarnet intravenously for 21 to 28 days. The oral formulation of ganciclovir or valganciclovir may be used if symptoms are not severe enough to interfere with oral absorption (Benson et al., 2004). Ganciclovir is recommended for maintenance, since it is more cost effective and has fewer side effects (Somerville, 2003).
A broad-spectrum antiinfective, such as ciprofloxacin or metronidazole, may be initiated if findings of studies are negative (Woodruff & Glare, 2003). Antiviral agents should also be considered when culture results are negative. However, remember that the protease inhibitors nelfinavir and ritonavir commonly cause diarrhea (Cohen et al., 2001).
If diarrhea is caused by fat malabsorption, consider administering pancreatic enzymes. The starting dose of pancreatin or pancrelipase is two capsules or tablets orally with meals and one capsule or tablet with snacks. The dose can be increased to three capsules or tablets with meals, if needed (Hodgson & Kizior, 2004). Famotidine, an H 2 histamine receptor antagonist, has also been noted to increase fat absorption (Waller & Caroline, 2000). The recommended dose is 20 mg orally twice daily.
If the diarrhea is due to bile salt malabsorption, administer cholestyramine. This medication absorbs and combines with bile acids to form an insoluble complex that is then eliminated in the feces. Administer 4 to 8 g orally three times daily (Hodgson & Kizior, 2004; Waller & Caroline, 2000).

Treat Discomfort

Discomfort associated with diarrhea includes gas pain and colicky pain. Simethicone is helpful for gas-related discomfort. Anticholinergic medications treat most colicky pain effectively. Examples of anticholinergic medications include propantheline (Pro-Banthine), 15 mg orally two or three times daily; hyoscyamine (Anaspaz, Levsin), 0.125 to 0.25 mg orally three or four times daily; and dicyclomine (Antispas, Bentyl), 20 mg orally three or four times daily (Hodgson & Kizior, 2004).

Control Diarrhea

Because diarrhea can be protective by flushing out irritative substances, avoid antidiarrheals for acute diarrhea. Adsorbent agents, such as attapulgite (Kaopectate), work by taking up substances nonspecifically, including bacteria, toxins, and water. They may be helpful for mild diarrhea in the healthy population. However, the large volumes required and their moderate effectiveness make them undesirable for palliative care (Sykes, 2003).
Mucosal prostaglandin inhibitors are helpful for acute diarrhea that requires an antidiarrheal for comfort and for those that involve an inflammatory process (e.g., radiation enteritis). Any nonsteroidal antiinflammatory drug (NSAID), except indomethacin, may be helpful (Sykes, 2003). Bismuth subsalicylate (Pepto-Bismol) is also a mucosal prostaglandin inhibitor. The recommended dosage is 30 ml or 2 tablets orally every 30 to 60 minutes, not to exceed eight doses per day for more than 2 days. Another GI antiinflammatory medication is mesalamine (Asacol). Administer 2400 mg/day orally in divided doses (Hodgson & Kizior, 2004). Psyllium-containing products such as Metamucil may also be useful for their ability to absorb excess fluid within the bowel (Montagnini, 2004).
Opioids are the mainstay of general antidiarrheal treatment in palliative settings (Sykes, 2003). They work by decreasing intestinal motility, leading to increased fluid absorption. Loperamide is the preferred opioid for diarrhea as it does not cross the blood-brain barrier and therefore has the highest antidiarrheal-to-analgesic ratio of the opioid-like agents (Mercadante, 2002). Loperamide is also about three times more potent than diphenoxylate and 50 times more potent than codeine. It is also long-acting, requiring only twice-daily dosing when long-term management of diarrhea is required. Tincture of opium (paregoric), which is sometimes used when diarrhea is refractory to loperamide, crosses the blood-brain barrier and thus causes systemic opioid effects. The bitter taste of tincture of opium may be nauseating to some persons. Dosages for all of these opioid antidiarrheals are as follows:
▪ Loperamide (Imodium): initial dose of 4 mg, followed by 2 mg after each loose stool. The generally accepted maximal dose is 16 mg/day (Hodgson & Kizior, 2004; Sykes, 2003; Waller & Caroline, 2000).
▪ Diphenoxylate (in Lomotil): initial dose of 5 mg, followed by 2.5 to 5 mg orally four times daily, titrated to patient response (Hodgson & Kizior, 2004; Sykes, 2003).
▪ Codeine phosphate: 10 to 60 mg orally four times daily. Codeine is usually avoided due to systemic opioid effects, but it is inexpensive (Skyes, 2003).
▪ 10% Tincture of opium: 0.3 to 1 ml orally four times daily (Waller & Caroline, 2000).
Octreotide, an analogue of the hormone somatostatin, inhibits GI motility, pancreatic secretion, and intestinal absorption. It has been demonstrated to be effective in the management of chemotherapy-induced diarrhea, diarrhea associated with dumping syndrome, and chronic diarrhea not responsive to specific antimicrobial therapy (Rosenoff, 2004; Sykes, 2003). It has also been shown to be helpful in controlling diarrhea due to secretory tumors and celiac plexus block (Mercadante, 2002; Sykes, 2003). Side effects include nausea, pain at the injection site, and headache. Because octreotide is expensive, this medication is generally reserved for those whose condition is refractory to other interventions. Dosages range from 150 to 600 mcg/day subcutaneously, either in divided doses or by continuous infusion. Waller and Caroline (2000) suggest the following:
▪ For chemotherapy or radiation therapy–induced diarrhea, administer 100 mcg subcutaneously twice daily.
▪ For postgastectomy dumping syndrome, administer 300 mcg/day by continuous infusion.
▪ For carcinoid syndrome, administer 150 to 300 mcg SC twice daily or 300 to 600 mcg/day by continuous infusion.
Clonidine may be helpful for some secretory diarrheas. This medication probably acts on enterocytes to suppress the release of secretory substances. The side effects of hypotension and sedation may limit its usefulness in palliative care (Mercadante, 2002).

PATIENT AND FAMILY EDUCATION

Detailed information from the patient and family is required in order to assess the potential causes of diarrhea and plan appropriate interventions. The clinician must teach the importance of prompt and detailed reporting of any changes in bowel patterns:
▪ Discuss the importance of reporting bowel functioning, including frequency, amount, color, and consistency of stools and any discomforts associated with bowel movements, to the health care team.
▪ Encourage adequate oral fluid intake to replace fluid losses due to diarrhea.
Provide instruction on the purchase or preparation of fluids with sugar and electrolytes.
If intravenous hydration is required at home, provide instruction on intravenous catheter site care and maintenance of the intravenous fluids.
▪ Teach the following dietary modifications to lessen diarrhea, taking into consideration the patient’s desire and ability to eat.
Eat or provide small, frequent meals.
Avoid excessively hot, cold, or spicy foods.
Avoid caffeine.
Avoid milk products, fat, whole grains, and fresh fruits and vegetables.
Broaden the diet as tolerated, beginning with white bread, pasta, potatoes, rice, and fruits. The old mnemonic “BRAT” may be helpful in remembering acceptable foods: bananas, rice or rice cereals, applesauce, and toast.
In persons with a lactase deficiency, teach the use of lactose-free dairy products.
▪ Teach appropriate use of all medications, including antidiarrheals, anticholinergics, and antiinfective agents.
▪ Patients with prolonged diarrhea may require antidiarrheal medications on a schedule rather than as needed.
Instruction on giving subcutaneous injections or maintaining subcutaneous infusions is required for patients who are receiving octreotide.
▪ Discuss the importance of perianal care:
Teach the patient and family good, gentle cleansing techniques using a squeeze bottle of warm water.
Teach how to monitor for skin breakdown.
Teach appropriate use of skin barrier products.

EVALUATION AND PLAN FOR FOLLOW-UP

Frequently monitor the patient’s bowel status, hydration status, and level of comfort. If diarrhea continues after instituting a treatment, appropriate changes must occur in the treatment plan. Determine if the cause was not correctly diagnosed or if a different treatment might be more effective. Encourage patients whose diarrhea continues for several days to keep intake and output records. This will assist in evaluating the need for supplemental oral or parenteral fluids.
At all times the patient is evaluated for comfort, including abdominal pain due to gas or GI spasm and discomfort associated with skin excoriation. Encourage the patient to describe the type of abdominal discomfort so that appropriate interventions are prescribed. Teach good skin care to prevent skin excoriation and instruct the patient and caregivers to report skin discomfort or any changes in the condition of the skin.
CASE STUDY
The daughter of Mrs. A., an 82-year-old patient with advanced ovarian cancer, calls to report that her mother has had several bouts of diarrhea over the past 2 days. The daughter states that she gave her mother a few doses of loperamide (Imodium) both yesterday and today, but the diarrhea continues. She also reports that her mother is complaining of abdominal pain and cramping with the diarrhea. Mrs. A.’s medications include the following:
▪ Sustained-release oxycodone, 40 mg orally twice daily, with a rescue dose of oxycodone, 10 mg orally every 1 to 2 hours as needed for pain
▪ Docusate sodium–sennosides 50 mg/8.6 mg, 2 tablets orally at bedtime for constipation
▪ Lorazepam, 1 mg orally every 6 hours as needed for anxiety
▪ Digoxin, 0.125 mg orally daily for heart failure (well-controlled)
The clinician’s questions elicit the following information. The diarrhea is dark and has the consistency of mucus. It occurred in small amounts, “maybe a quarter of a cup or so,” five or six times over the past 24 hours. There is no pattern related to food intake. Mrs. A. is complaining of intermittent cramping pain in her lower abdomen and a sensation of rectal fullness: “like her bowels are still full even after the diarrhea.” The patient’s last regular bowel movement was 5 days ago.
The clinician tells the patient and family that the diarrhea is caused by a blockage of the bowel with hard stool. She explains the need for removal of the impaction, gives the patient an oil retention enema, and instructs the daughter to give Mrs. A. her lorazepam and immediate-release oxycodone. The clinician applies lidocaine jelly to the rectal area.
While waiting for the stool to soften as much as possible with the enema and for the medications to begin to work, the clinician explains that the combination of the pain medication and decreased fluid intake caused this blockage. The clinician discusses the following instructions with the patient and family:
▪ Increase the docusate sodium–sennosides 50 mg/8.6 mg to 2 tablets orally twice daily.
▪ Monitor bowel movements:
▪ If no bowel movement occurs in 2 days, give a 10-mg bisacodyl suppository. If there are no results, call the clinician.
▪ If diarrhea occurs, call the clinician.
▪ Increase fluid intake by mouth, as tolerated:
▪ Mix a solution of ½ teaspoon salt, ½ teaspoon baking soda, and 4 tablespoons sugar in 1 liter of water. Mrs. Anderson should sip the drink during the day, aiming to drink 1 liter of the fluid each day. Keep this solution refrigerated and discard any unused solution after 24 hours.
▪ If the patient is unable to drink at least 1 liter a day, contact the clinician.
The clinician also writes these instructions because the patient’s discomfort and medications may interfere with her ability to understand and remember information at the present time.
Now that the local anesthetic and oil retention enema have had time to be effective, the clinician digitally removes the impaction and gives a cleansing enema. The nurse cleans the rectal area with a squeeze bottle of warm water and applies a silicone-based skin barrier cream to the reddened but intact skin. She reinforces the instructions and plans a follow-up telephone call in the morning.
Aberg, J.A.; Williams, P.L.; Liu, T.; et al.AIDS Clinical Trial Group 393 Study Team, A study of discontinuing maintenance therapy in human immunodeficiency virus-related subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team, J Infect Dis 187 (7) ( 2003) 10461052.
Anastasi, J.K.; Capili, B., HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations, Am J Infect Control 28 (2000) 262266.
Benson, C.A.; Kaplan, J.E.; Masur, H.; et al., Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases of Society of America, Retrieved November 15, 2005, from www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm ( 2004).
Bickley, L.S., The abdomen, In: (Editor: Bickley, L.S.) Bates’ guide to physical examination and history taking8th ed. ( 2004)Lippincott, Philadelphia, pp. 355386.
Carpenito, L.J., Nursing diagnosis: Application to clinical practice. 8th ed. ( 2000)Lippincott, Philadelphia.
Cohen, J.; West, A.B.; Bini, E.J., Infectious diarrhea in human immunodeficiency virus, Gastroenterol Clin North Am 30 (3) ( 2001) 637664.
Fleck, C.A., Ethical wound management for the palliative patient, Extended Care Product News 100 (4) ( 2005) 3846.
Hodgson, B.B.; Kizior, R.J., Saunders nursing drug handbook 2004. ( 2004)Saunders, St. Louis.
Levy, M.H., Constipation and diarrhea in cancer patients, Cancer Bull 43 (1991) 412422.
Lingappa, V.R., Gastrointestinal disease, In: (Editors: McPhee, S.J.; Lingappa, V.R.; Ganong, W.F.) Pathophysiology of disease: An introduction to clinical medicine4th ed. ( 2003)Lange Medical Books/McGraw-Hill, New York, pp. 340379.
Maggi, P.; Larocca, A.M.; Quarto, M.; et al., Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1, Eur J Clin Microbiol Infect Dis 19 (2000) 213217.
Mercadante, W., Diarrhea, malabsorption, and constipation, In: (Editors: Berger, A.; Portenoy, R.; Weissman, D.) Principles and practice of palliative and supportive oncology2nd ed. ( 2002)Lippincott Williams & Wilkins, Philadelphia, pp. 233249.
Montagnini, M., Non-pain symptom management in palliative care, Clin Fam Pract 6 (2) ( 2004) 395422.
Poutanen, S.M., Clostridium difficile-associated diarrhea in adults, Can Med Assoc J 171 (1) ( 2004) 5158.
Rogers, H.M., Management of clients with intestinal disorders, In: (Editors: Black, J.M.; Hawks, J.H.) Medical-surgical nursing: Clinical management for positive outcomes7th ed. ( 2005)Elsevier Saunders, St. Louis, pp. 807855.
Rosenoff, S.H., Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy, Eur J Cancer Care (Engl) 13 (4) ( 2004) 380383.
Sanchez, T.H.; Brooks, J.T.; Sullivan, P.S.; et al.Adult/Adolescent Spectrum of HIV Disease Study Group, Bacterial diarrhea in persons with HIV disease, United States, 1992-2002, Clin Infect Dis 41 (11) ( 2005) 16211627.
Somerville, K.T., Cost advantages of oral drug therapy for managing cytomegalovirus disease, Am J Health-Sys Pharm 60 (23 Suppl 8) ( 2003) S9S12.
Sykes, N., Constipation and diarrhoea, In: (Editors: Doyle, D.; Hanks, G.; Cherny, N.I.; Calman, K.) Oxford textbook of palliative medicine3rd ed. ( 2003)Oxford University Press, New York, pp. 483496.
Verdier, R.; Fitzgerald, D.; Johnson, W.; et al., Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients: A randomized controlled trial, Ann Intern Med 132 (2000) 885888.
Waller, A.; Caroline, N.L., Handbook of palliative care in cancer. 2nd ed. ( 2000)Butterworth-Heinemann, Boston.
Woodruff, R.; Glare, P., AIDS in adults, In: (Editors: Doyle, D.; Hanks, G.; Cherny, N.I.; et al.) Oxford textbook of palliative medicine3rd ed. ( 2003)Oxford University Press, New York, pp. 847880.